Skip to content

Gilles Andre Salles

The University of Sydney

3 papers in the Anchorcite directory, published between 2002 and 2018, cited 17,935 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Steven H. Swerdlow · 1 paper
  • Elías Campo · 1 paper
  • Stefano Aldo Pileri · 1 paper
  • Nancy L. Harris · 1 paper
  • Harald Stein · 1 paper
  • Reiner Siebert · 1 paper
  • Ranjana H. Advani · 1 paper
  • Michele E. G. Ghielmini · 1 paper

Papers

  1. The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood · 2016 · 8,061 citations

    A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the…

  2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine · 2002 · 5,644 citations

    BACKGROUND: The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conducted a randomized trial to…

  3. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine · 2018 · 4,230 citations

    BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells…

Metadata from OpenAlex (CC0).